IPP Bureau

CORONA Remedies receives EU-GMP certification for hormone facility
CORONA Remedies receives EU-GMP certification for hormone facility

By IPP Bureau - June 02, 2026

Accreditations for Bhayla manufacturing site strengthen the company’s global quality credentials and support expansion of its hormone portfolio into regulated international markets

Marksans Pharma to acquire Netherlands-based QliniQ
Marksans Pharma to acquire Netherlands-based QliniQ

By IPP Bureau - June 02, 2026

Acquisition provides direct access to the Dutch healthcare market, enhancing Marksans’ sales, distribution and market-access capabilities across regulated European markets

FDA okays AstraZeneca’s bladder cancer drug Imfinzi Plus BCG
FDA okays AstraZeneca’s bladder cancer drug Imfinzi Plus BCG

By IPP Bureau - June 02, 2026

First immunotherapy combination approved in the US for BCG-naïve high-risk NMIBC demonstrates a 32% reduction in the risk of disease recurrence, progression, or death

Scientists develop rapid nanosensor to detect gut health biomarker for IBD and diabetes
Scientists develop rapid nanosensor to detect gut health biomarker for IBD and diabetes

By IPP Bureau - June 02, 2026

Novel fluorescent nanosensor enables real-time detection of indole-3-propionic acid (IPA), paving the way for faster gut health screening, point-of-care diagnostics, and wearable monitoring devices

Moderna and Merck’s mRNA cancer vax combo shows 5-year survival in melanoma trial
Moderna and Merck’s mRNA cancer vax combo shows 5-year survival in melanoma trial

By IPP Bureau - June 02, 2026

An exploratory overall survival signal also leaned in favor of the combination, though the companies noted the result remains preliminary

CellCarta and Leica Biosystems expand push to streamline precision medicine development
CellCarta and Leica Biosystems expand push to streamline precision medicine development

By IPP Bureau - June 02, 2026

The collaboration introduces a flexible, end-to-end CDx framework designed to adapt to shifting regulatory environments

BioNTech and Bristol Myers Squibb drug shows strong early signal in lung cancer trial
BioNTech and Bristol Myers Squibb drug shows strong early signal in lung cancer trial

By IPP Bureau - June 02, 2026

The safety profile was described as manageable, though not without notable toxicities

Eli Lilly drug slashes lung cancer recurrence risk by 83% in landmark phase 3 trial
Eli Lilly drug slashes lung cancer recurrence risk by 83% in landmark phase 3 trial

By IPP Bureau - June 02, 2026

The trial results are for the pharma powerhouse's RET-targeted therapy Retevmo (selpercatinib)

Ebola vax on the anvil?
Ebola vax on the anvil?

By IPP Bureau - June 02, 2026

CEPI will commit up to US $50 million to fund preclinical research and Phase 1 clinical trials of Moderna’s mRNA-based vaccine candidate

Hyderabad gets new 'Oval' fertility hub
Hyderabad gets new 'Oval' fertility hub

By IPP Bureau - June 02, 2026

Fertility platform launches flagship clinic with advanced IVF tech

Yoginii partners with Panacea Biotec to expand wellness portfolio
Yoginii partners with Panacea Biotec to expand wellness portfolio

By IPP Bureau - June 02, 2026

Collaboration brings Staart Prime, ChilRun and NikoMom products to Yoginii’s platform, strengthening its family-focused wellness ecosystem and supporting women through motherhood and family care

M|O|C Cancer Care’s research gains global recognition at ASCO 2026
M|O|C Cancer Care’s research gains global recognition at ASCO 2026

By IPP Bureau - June 02, 2026

The accepted studies span several critical areas of oncology, including nutrition, genomics, precision medicine, patient-reported outcomes, and community-based cancer care

Bristol Myers Squibb wins EU approval for Opdivo-based frontline treatment in advanced hodgkin lymphoma
Bristol Myers Squibb wins EU approval for Opdivo-based frontline treatment in advanced hodgkin lymphoma

By IPP Bureau - June 02, 2026

The approval is supported by results from the Phase 3 SWOG 1826 trial

STRIDE-based regimens show survival momentum in EMERALD-3 liver cancer trial
STRIDE-based regimens show survival momentum in EMERALD-3 liver cancer trial

By IPP Bureau - June 02, 2026

While overall survival data remain immature, the results pointed to a favourable trend.

Aragen completes commercial-scale GMP manufacturing of Daretabart in 9 months
Aragen completes commercial-scale GMP manufacturing of Daretabart in 9 months

By IPP Bureau - June 02, 2026

Anti-GD2 monoclonal antibody for high-risk neuroblastoma advances toward BLA submission following successful tech transfer from California to Bengaluru

Latest Stories

Interviews

Packaging